ImageneBio (IMA) Share-based Compensation (2020 - 2025)
ImageneBio (IMA) posted Share-based Compensation of $7.5 million for Q3 2025, up 316.67% sequentially from $1.8 million in Q2 2025, and up 637.46% YoY from $1.0 million in Q3 2024.
ImageneBio (IMA) Share-based Compensation (2020 - 2025) Analysis & Trends
ImageneBio has reported Share-based Compensation for 6 years, with the latest figure at $7.5 million in Q3 2025.
- Quarterly Share-based Compensation rose 637.46% year-over-year to $7.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.5 million (up 23.93% YoY) and the FY2024 annual result came in at $5.3 million, down 52.72% from the prior year.
- Share-based Compensation rose to $7.5 million in Q3 2025 per IMA's latest filing, from $1.8 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $7.5 million in Q3 2025 and troughed at $57000.0 in Q1 2025.
- A 5-year average of $2.1 million and a median of $1.8 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 637.46% in 2025, down 97.15% in 2025.
- Over 5 years, Share-based Compensation stood at $1.6 million in 2021, then increased by 17.58% to $1.9 million in 2022, then slipped by 5.59% to $1.8 million in 2023, then jumped by 201.71% to $5.3 million in 2024, then soared by 41.64% to $7.5 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $7.5 million, $1.8 million, and $57000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | ImageneBio | 48.35 Mn | -87.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.50 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Dec 31, 2024 | 5.30 Mn |
| Dec 31, 2024 | 5.30 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | 1.88 Mn |